SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Meta Expands AI Training With Employee Activity Tracking Tools 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
REHOVOT, Israel, March 02, 2016 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 36th Annual Health Care Conference taking place in Boston, Massachusetts from March 7 – 9, 2016. Dr. Lieberman’s presentation will take place on Wednesday, March 9, at 11:20am ET.
- 28th Annual ROTH Conference taking place in Dana Point, California from March 13 – 16, 2016. Dr. Lieberman’s presentation will take place on Monday, March 14 at 9:30am PT, 12:30pm ET.
To access the live webcast of the presentations, please visit ir.neuroderm.com/. A replay will be available following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD MBA, CEO
[email protected]
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1762
